minktherapeutics.com - INKT Income before deduction of interest, taxes and amortization

Graphic logo of MiNK Therapeutics Inc. (INKT)

The success of MiNK Therapeutics, Inc. (INKT) is based on the efficacy of iNKT cells and the scaling of agenT-797, as well as the establishment of scientific alliances with oncology centers. EBITDA fluctuations over the time trajectory on the GURU.Markets chart demonstrate the influence of these factors, with the metric recorded at 0.00. The security of intellectual property and the humanitarian status of the therapy in the US minimize geopolitical risks.

Profit before payment of interest, taxes and amortization: MiNK Therapeutics, Inc. (INKT) for 11/23/2025 - 11/17/2026

MiNK Therapeutics Inc. - analytical breakdowns and key metrics (INKT)

- market value and analyst target forecast:
Analysis of all company metrics:minktherapeutics.com - INKT
Mass-produced product of MiNK Therapeutics

This metric measures net cash flow from operating activities before accounting for asset depreciation and debt obligations, determining the business's actual capacity for resource generation. In the context of MiNK Therapeutics, Inc. (INKT), the EBITDA_Co valuation reflects clinical trial progress rather than market cycles, allowing investors to differentiate the company's fundamental growth from speculative share price volatility.

Competitors of MiNK Therapeutics, Inc. (INKT)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (Janux Therapeutics, Inc.)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization tangotx.com|Operating profit before deduction of amortization iovance.com (IOVA)|Profit before payment of interest, taxes and amortization Immatics NV (IMTX)|Operating profit before deduction of amortization Xencor Corp XNCR|Compass Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Inc. REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (innate-pharma.com) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen Ltd. (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Profit before interest, taxes and amortization|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus Pharma - Income before deduction of interest, taxes and amortization|LVTX (Lava Tx) - Operating profit EBITDA|Operating profit EBITDA NextCure Inc|Profit before payment of interest, taxes and amortization leaptx.com (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization